The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Fibrate treatment for primary biliary cirrhosis
Abstract
Purpose of review Primary biliary cirrhosis (PBC) can lead to end-stage liver disease and death. Ursodeoxycholic acid (UDCA) treatment can normalize serum liver enzymes in PBC, and such UDCA-responsive patients have a similar life expectancy as age and sex-matched controls. Nearly up to 50% of the patients with PBC, depending on sex and age at diagnosis, show an incomplete biochemical response to UDCA and require additional/alternative treatment. The purpose of this review is to critically evaluate the molecular mechanisms and clinical benefit of fibrate treatment in these patients. Recent findings Fibrates have anticholestatic, anti-inflammatory, and antifibrotic effects in animal and in-vitro studies. The mechanisms that underlie these effects are complementary, and largely mediated through activation of peroxisome proliferator activated receptors. Fibrate treatment ameliorated liver biochemical tests in UDCA unresponsive patients, either as mono-therapy or in combination with UDCA. These results, however, were obtained in case series and small pilot studies. The results of phase III studies, such as the Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (BEZURSO) trial, are currently awaited. Summary A considerable body of observational evidence supports the safety and efficacy of fibrate treatment in PBC patients with an incomplete response to UDCA. These results encourage the evaluation of its effects on liver-related morbidity and mortalit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network
Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., & Mangelsdorf, D. J. (2006) · Cell · doi:10.1016/j.cell.2006.06.049 · Cited by 1,015
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Research works printed but not linked: 7
- Rudic, 2012, Cochrane Database Syst Rev, 12, CD000551
- Mason, 2010, Hepatology, 52, 357A
- Hirschfield, 2011, Hepatology, 54, 429A
- Marra, 2005, World J Gastroenterol, 11, 4931
- Kanda, 2003, astroenterol, 38, 573
- Yano, 2002, astroenterol, 97, 1075
- Miyaguchi, 2000, epatogastroenterology, 47, 1518
Cited by
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Self-citationLakhia, R., Yheskel, M., Flaten, A., Quittner-Strom, E. B., Holland, W. L., & Patel, V. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00352.2017 · Cited by 140
Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
Metadata
- Authors
- Cuperus, F. J. C., Halilbasic, E., & Trauner, M.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Trauner, Michael
- Venue
- Current Opinion in Gastroenterology
- Published
- 2014-05
- Volume
- 30
- Issue
- 3
- Pages
- 279-286
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2171885360
- Cited by
- 36
- References
- 91
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary biliary cirrhosis, fibrate therapy, bezafibrate, ursodeoxycholic acid, peroxisome proliferator-activated receptors, antifibrotic effect, anti-inflammatory activity, combination therapy, liver enzymes
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Hypolipidemic Agents, Drug Therapy, Combination, Humans, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Treatment Outcome, Treatment Failure, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrate treatment for primary biliary cirrhosis. https://app.cochat.ai/papers/10.1097/mog.0000000000000056
- The paper
- Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014). Fibrate treatment for primary biliary cirrhosis. Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.